Pharmaceutical Composition Containing Lutein and Antioxidant for Treating and Preventing Human Disease

• US 20150320699A1
• Filed: 05/08/2014
• Published: 11/12/2015
• Est. Priority Date: 05/08/2014
• Status: Active Grant

• Current Assignee: Yaguang Liu
• Original Assignee: Yaguang Liu
• Inventors: Liu, Yaguang
• Granted Patent: US 9,622,970 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/047 having two or more hydroxy groups, e.g. sorbitol
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5078 with drug-free core

Abstract

The present invention is to providing a new preparation including complex of a medical compound with lutein, astaxanthin and antioxidant. The new preparation includes stabilized liposome preparation, sustained release preparation and polymeric micelles preparation which used as delivery systems for lutein, astaxanthin and antioxidant. The new preparation significantly increases bioavailability of lutein and astaxanthin and uses for treatment and prevention of eyes and other disease.

Claims

1. A pharmaceutical preparation for increasing bioavailability and solubility of lutein and astaxanthin Comprising and effective amount of polymeric micelles, stabilized liposome and sustained release pharmaceutical composition.

2. The pharmaceutical preparation of claim 1 wherein said pharmaceutical preparation is in the form of polymeric micelles preparation of lutein.

3. The pharmaceutical preparation of claim 1 wherein said pharmaceutical preparation is in the form of sustained release pharmaceutical preparation of lutein.

4. The pharmaceutical preparation of claim 1 wherein said pharmaceutical preparation is in the form of lutein-containing sterically stabilized liposomes preparation.

5. The pharmaceutical preparation of claim 1 wherein said pharmaceutical preparation is in the form of polymeric micelles preparation of astaxanthin.

6. The pharmaceutical preparation of claim 1 wherein said pharmaceutical preparation is in the form of sustained release pharmaceutical preparation of astaxanthin.

7. The pharmaceutical preparation of claim 1 wherein said pharmaceutical preparation is in the form of astaxanthin-containing sterically stabilized liposomes preparation.

8. The pharmaceutical preparation of claim 1, wherein said lutein and astaxanthin are both present at 50% by weight of sustained release pharmaceutical.

9. The pharmaceutical preparation of claim 1, wherein said lutein and astaxanthin are both present at 50% by weight of sterically stabilized loposomes preparation.

10. The pharmaceutical preparation of claim 1, wherein said lutein and astaxanthin are both present at 50% by weight of polymeric micelles preparation.

11. A dosage unit according to claim 1 wherein said dosage form is a tablet which includes in addition pharmaceutically acceptable binders and excipients.

12. A dosage unit according to claim 1 wherein said dosage form is a syrup or elixir which includes in addition a liquid vehicle suitable for oral administration.

13. A pharmaceutical preparation of lutein-containing polymeric micelles or astaxanthin-containing polymeric micelles in the form of nano-sized micelles for treating eye'"'"'s and other disease, wherein said pharmaceutical preparation consists of natural polymers for self-assembling polymeric micelles preparation.

14. The pharmaceutical preparation of claim 13, wherein said pharmaceutical preparation consists of soy polypeptide (SPP) and poly-sodium Haidai (PSH) to create the polymeric micelles.

15. The pharmaceutical composition of claim 13, wherein said SPP and PSH are very safe, natural biodegradable, inexpensive and renewable polymers.

16. The pharmaceutical composition of claim 13, wherein said SPP extracted from natural soybean only and it is not obtained from transfer-gene seeds.

17. The pharmaceutical composition of claim 13, wherein said PSH is linear polymer and molecular weight of PSH is about 240000.

18. A method for preparing a release preparation, said method comprising:

a. dissolving polyvinylpyrrolidone in isopropanol,

b. adding lutein to the mixture of part (a),

c. mixing sugar into mixture produced by part (b), and

d. coating said mixture with a water insoluble compound selected from the group consisting of ethyl cellulose, cellulose acetate butyrate and cellulose triacetate.

19. The method for preparing a release preparation, according to claim 18, wherein said, method comprising:

a. dissolving polyvinylpyrrolidone in isopropanol,

b. adding astaxanthin to the mixture of part (a),

c. mixing sugar into mixture produced by part (b), and

d. coating said mixture with a water insoluble compound selected from the group consisting of ethyl cellulose, cellulose acetate butyrate and cellulose triacetate.

20. The method for preparing a release preparation, according to claim 18, wherein said, method comprising:

a. dissolving polyvinylpyrrolidone in isopropanol,

b. adding lutein plus astaxanthin to the mixture of part (a),

c. mixing sugar into mixture produced by part (b), and

d. coating said mixture with a water insoluble compound selected from the group consisting of ethyl cellulose, cellulose acetate butyrate and cellulose triacetate.